These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33715892)

  • 1. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
    Rocconi RP; Monk BJ; Walter A; Herzog TJ; Galanis E; Manning L; Bognar E; Wallraven G; Stanbery L; Aaron P; Senzer N; Coleman RL; Nemunaitis J
    Gynecol Oncol; 2021 Jun; 161(3):676-680. PubMed ID: 33715892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Walter A; Rocconi RP; Monk BJ; Herzog TJ; Manning L; Bognar E; Wallraven G; Aaron P; Horvath S; Tang M; Stanbery L; Coleman RL; Nemunaitis J
    Gynecol Oncol; 2021 Dec; 163(3):459-464. PubMed ID: 34702567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.
    Sliheet E; Robinson M; Morand S; Choucair K; Willoughby D; Stanbery L; Aaron P; Bognar E; Nemunaitis J
    Cancer Gene Ther; 2022 Jul; 29(7):993-1000. PubMed ID: 34785763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Rocconi RP; Grosen EA; Ghamande SA; Chan JK; Barve MA; Oh J; Tewari D; Morris PC; Stevens EE; Bottsford-Miller JN; Tang M; Aaron P; Stanbery L; Horvath S; Wallraven G; Bognar E; Manning L; Nemunaitis J; Shanahan D; Slomovitz BM; Herzog TJ; Monk BJ; Coleman RL
    Lancet Oncol; 2020 Dec; 21(12):1661-1672. PubMed ID: 33271095
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Mirza MR; Lindahl G; Mahner S; Redondo A; Fabbro M; Rimel BJ; Herrstedt J; Oza AM; Canzler U; Berek JS; González-Martín A; Follana P; Lord R; Azodi M; Estenson K; Wang Z; Li Y; Gupta D; Matulonis U; Feng B
    Cancer Res Commun; 2022 Nov; 2(11):1436-1444. PubMed ID: 36970052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
    Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Zhang Y; Zhang L; Zhao Y; Wang S; Feng L
    Front Oncol; 2022; 12():945867. PubMed ID: 36338747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.
    Barve M; Aaron P; Manning L; Bognar E; Wallraven G; Horvath S; Stanbery L; Nemunaitis J
    Clin Med Insights Oncol; 2022; 16():11795549221110501. PubMed ID: 35957960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials.
    Purwar R; Ranjan R; Pal M; Upadhyay SK; Kumar T; Pandey M
    World J Surg Oncol; 2023 May; 21(1):157. PubMed ID: 37217940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
    Rocconi RP; Stanbery L; Tang M; Madeira da Silva L; Walter A; Monk BJ; Herzog TJ; Coleman RL; Manning L; Wallraven G; Horvath S; Bognar E; Senzer N; Brun S; Nemunaitis J
    Commun Med (Lond); 2022; 2():106. PubMed ID: 36051466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Harter P; Mouret-Reynier MA; Pignata S; Cropet C; González-Martín A; Bogner G; Fujiwara K; Vergote I; Colombo N; Nøttrup TJ; Floquet A; El-Balat A; Scambia G; Guerra Alia EM; Fabbro M; Schmalfeldt B; Hardy-Bessard AC; Runnebaum I; Pujade-Lauraine E; Ray-Coquard I
    Gynecol Oncol; 2022 Feb; 164(2):254-264. PubMed ID: 34952708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
    Oh J; Barve M; Matthews CM; Koon EC; Heffernan TP; Fine B; Grosen E; Bergman MK; Fleming EL; DeMars LR; West L; Spitz DL; Goodman H; Hancock KC; Wallraven G; Kumar P; Bognar E; Manning L; Pappen BO; Adams N; Senzer N; Nemunaitis J
    Gynecol Oncol; 2016 Dec; 143(3):504-510. PubMed ID: 27678295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
    Zhu J; Ke G; Bi R; Wu X
    J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group.
    Lai CH; Vallikad E; Lin H; Yang LY; Jung SM; Liu HE; Ou YC; Chou HH; Lin CT; Huang HJ; Huang KG; Qiu J; Hung YC; Wu TI; Chang WY; Tan KT; Lin CY; Chao A; Chang CJ
    J Gynecol Oncol; 2020 Jan; 31(1):e5. PubMed ID: 31788995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
    Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
    Rocconi RP; Stevens EE; Bottsford-Miller JN; Ghamande SA; Elder J; DeMars LL; Munkarah A; Aaron P; Stanbery L; Wallraven G; Bognar E; Manley M; Horvath S; Manning L; Walter A; Galanis E; Herzog T; Monk BJ; Coleman RL; Nemunaitis J
    Cancer Gene Ther; 2022 Mar; 29(3-4):369-382. PubMed ID: 33753870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic and predictive value of homologous recombination deficiency status in patients with advanced stage epithelial ovarian carcinoma after first-line platinum-based chemotherapy.
    Xu Y; Chen YA; Wu Y; Saverimuthu A; Jadhav A; Bhuiyan R; Sandler J; Yio J; Kumar V
    Front Oncol; 2024; 14():1372482. PubMed ID: 38915363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
    Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
    Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    Aghajanian C; Bookman MA; Fleming GF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Jackson CG; Sullivan D; Ratajczak CK; Coleman RL
    Gynecol Oncol; 2021 Aug; 162(2):375-381. PubMed ID: 34112513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.